As an independent student newspaper and the paper of record for the city of Berkeley, the Daily Cal has been communicating important updates during this pandemic. Your support is essential to maintaining this coverage.
UC Berkeley researchers and their collaborators found hundreds of relatively large viruses with genome sizes thought to only be characteristic of living organisms.
Read More…
UC Berkeley professor of molecular and cell biology and of chemistry Jennifer Doudna has been awarded the 2020 Wolf Prize in Medicine for her discovery of CRISPR-Cas9 gene-editing tool.
Read More…
The United States Patent and Trademark Office issued the UC system’s 20th CRISPR-Cas9 gene-editing technology patent with the arrival of the new year, according to a press release by Berkeley News.
Read More…
This month, UC Berkeley scientists genetically modified fruit flies using CRISPR-Cas9 gene-editing technology, granting the flies immunity to toxic milkweed and allowing them to use the toxins from the milkweed as a defense mechanism against predators.
Read More…
The UC system was awarded a patent Tuesday, marking the university’s 16th patent for the CRISPR-Cas9 patent portfolio — the highest number in the country.
Read More…
An error in the UK Biobank resulted in a request for the retraction of a UC Berkeley professor’s paper with implications on past CRISPR research Friday.
Read More…
The UC system and partners University of Vienna and Emmanuelle Charpentier were awarded a 12th patent for the CRISPR-Cas9 gene-editing technology.
Read More…
By the end of the summer, the UC system expects to receive five more patents, raising its portfolio to 15 total patents related to CRISPR technology.
Read More…
The UC’s family of eight patents covers CRISPR methods for editing genes in any environment, whether the cells are in a plant, an animal or a human. This newest patent focuses specifically on the use of CRISPR gene editing within cells.
Read More…
The Patent Trial and Appeal Board of the U.S. Patent and Trademark Office announced an interference between multiple UC and multiple Broad Institute patents, a signal that the USPTO will resolve the seven-year ownership debate regarding CRISPR-Cas9 genome editing in eukaryotic cells.
Read More…
